Schizophrenia remains one of the most challenging psychiatric disorders, affecting thought, emotion, and social functioning. In a recent comprehensive review published in a leading journal, researchers from Peking University Sixth Hospital delve into the complex mechanisms underlying schizophrenia, which are from neurotransmitter dysregulation and neurodevelopmental anomalies to immune dysfunction and genetic susceptibility.
The article emphasizes that while dopamine-targeting antipsychotics are the mainstay of treatment, their limitations in treating negative and cognitive symptoms necessitate novel approaches. Promising directions include TAAR1 agonists like Ulotaront, muscarinic M1/M4 modulators such as KarXT, NMDA receptor enhancers like Iclepertin, anti-inflammatory agents, and probiotics targeting the gut-brain axis.
The review also covers advances in neuroimaging, electrophysiology, and multi-omics studies, which are crucial for understanding disease progression and personalizing treatment. These insights are vital for developing next-generation therapies that go beyond symptom management to address the root causes of schizophrenia.
Journal
Science China Life Sciences
Method of Research
Literature review